Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00250926 · OUTCOME

Time to Best Response

Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia · Source last updated 2016-04-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
Full Range
Time frame
33.2 months

Groups in this outcome

Bortezomib, Dexamethasone, Rituximab

A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy. Bortezomib: Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles Dexamethasone: Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles Rituximab: Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bortezomib, Dexamethasone, Rituximab23

Reported measurements

Source class 1
Values in Months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Bortezomib, Dexamethasone, Rituximab15Not reported0.726Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.7
        upper Limit
        26
        value
        15
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    units
    Participants
dispersion Type
Full Range
groups
  1. description
    A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy. Bortezomib: Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles Dexamethasone: Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles Rituximab: Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
    id
    OG000
    title
    Bortezomib, Dexamethasone, Rituximab
param Type
MEDIAN
reporting Status
POSTED
time Frame
33.2 months
title
Time to Best Response
type
PRIMARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice